The Week

XLV closed the week at $176.71, up 3.45% over the five sessions, while the S&P 500 fell 1.95%. That put the fund roughly 5.4 percentage points ahead of the benchmark. The path was not straight up: Monday opened at $171.49 and ended slightly higher, Tuesday pulled back to $169.66 and touched the week’s low of $169.48, then the fund rallied through Wednesday and Thursday, hitting a high of $178.86 on Thursday before easing to $176.71 on Friday. The overall pattern was a dip followed by a rebound toward the top of the range, with healthcare attracting buyers as technology stocks sold off.

Sector News

The sector’s strength coincided with a rotation out of AI names and into defensive pockets of the market. The S&P 500 Health Care Index reached an all-time high on Thursday, rising 2.8% on the day, and large-cap pharma stocks traded near or at record levels. Johnson & Johnson’s quarterly update showed innovative medicine performing strongly enough to offset MedTech headwinds, with full-year revenue poised to top $100 billion for the first time. UnitedHealth’s call pointed to stable medical cost trends; Mizuho named the stock a top pick, while TD Cowen stayed more cautious. Eli Lilly’s Omvoh posted positive one-year ulcerative colitis data, and its GLP-1 pill received backing from the EU drug regulator. AbbVie’s Skyrizi is under FDA review for subcutaneous induction dosing in Crohn’s disease, while J&J’s Tremfya demonstrated sustained remission through three years in a Phase 3 study. A hotter-than-expected CPI print initially pressured equities, but money then moved into healthcare and consumer staples, underscoring the defensive bid.

The Week Ahead

The macro calendar next week is mostly housing and energy data. Monday brings the NAHB housing market index, with prior and forecast both at 32. Tuesday sees housing starts, forecast at 1.305 against a prior of 1.275, and building permits, forecast at 1.395 versus a prior of 1.403. Wednesday brings the EIA weekly crude oil and Cushing inventory reports. For healthcare, the main threads from this week will carry over: J&J and UnitedHealth have already reported, but follow-through on Eli Lilly’s European regulatory progress and further clinical readouts from pharma names could keep the sector in focus.

In Short

XLV’s gain came against a falling tape, with the S&P 500 down 1.95% and the healthcare index hitting a record as money rotated out of AI. Valuation sits near neutral for the sector, with a latest P/E of about 17.75x and a P/B of about 1.37x. In the most recent session, large and medium orders were net buyers while small orders were net sellers, suggesting larger participants leaned into the defensive rotation. The key question is whether healthcare’s relative strength holds, and whether next week’s macro prints shift overall risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.